Charles Schwab Investment Management Inc. Increases Position in Cardlytics, Inc. (NASDAQ:CDLX)

Charles Schwab Investment Management Inc. grew its holdings in shares of Cardlytics, Inc. (NASDAQ:CDLX) by 3.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 402,552 shares of the company’s stock after purchasing an additional 12,209 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Cardlytics were worth $1,493,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in CDLX. Geode Capital Management LLC increased its stake in shares of Cardlytics by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock worth $3,371,000 after purchasing an additional 73,484 shares in the last quarter. RBF Capital LLC grew its holdings in Cardlytics by 311.9% during the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after purchasing an additional 369,620 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in Cardlytics by 56.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 317,644 shares of the company’s stock valued at $1,016,000 after purchasing an additional 113,966 shares during the period. Barclays PLC increased its position in Cardlytics by 223.9% in the third quarter. Barclays PLC now owns 58,026 shares of the company’s stock worth $186,000 after buying an additional 40,112 shares in the last quarter. Finally, Check Capital Management Inc. CA grew its stake in shares of Cardlytics by 11.0% during the 4th quarter. Check Capital Management Inc. CA now owns 56,200 shares of the company’s stock valued at $209,000 after acquiring an additional 5,550 shares during the period. 68.10% of the stock is owned by institutional investors.

Insider Activity at Cardlytics

In related news, CFO Alexis Desieno sold 8,854 shares of the firm’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $3.67, for a total transaction of $32,494.18. Following the completion of the transaction, the chief financial officer now owns 121,976 shares of the company’s stock, valued at $447,651.92. This trade represents a 6.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Amit Gupta sold 15,160 shares of the company’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $3.92, for a total transaction of $59,427.20. Following the completion of the sale, the chief executive officer now directly owns 215,494 shares in the company, valued at approximately $844,736.48. The trade was a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 111,454 shares of company stock valued at $391,864 in the last three months. 4.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on CDLX shares. Lake Street Capital reduced their target price on Cardlytics from $5.00 to $3.00 and set a “hold” rating on the stock in a report on Thursday, March 13th. Evercore ISI decreased their price objective on Cardlytics from $4.00 to $3.00 and set an “in-line” rating on the stock in a report on Thursday, March 13th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a report on Thursday, March 13th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $6.42.

Cardlytics Trading Down 8.0 %

NASDAQ CDLX opened at $1.85 on Friday. Cardlytics, Inc. has a 52 week low of $1.77 and a 52 week high of $15.89. The company has a 50 day moving average price of $2.81 and a 200 day moving average price of $3.39. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. The firm has a market cap of $96.36 million, a PE ratio of -0.30 and a beta of 1.62.

Cardlytics Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.